![Placeholder Image Placeholder Image](https://prod1.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
-
Media ReleaseNovartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
-
Media ReleaseNovartis steigert Umsatz um 12% und operatives Kernergebnis um 21% (fortzuführende Geschäftsbereiche, kWk¹). Sandoz abgespalten, wichtige Innovationsmeilensteine erreicht und Prognose 2023 erhöht
-
Media ReleaseNovartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
-
Media ReleaseNovartis : hausse de 12% du chiffre d’affaires et de 21% du résultat opérationnel core (tcc¹). Spin-off de Sandoz, étapes importantes de l’innovation ; hausse des prévisions pour 2023
-
Media ReleaseNovartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
-
Media ReleaseNovartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
-
Media ReleaseSandoz veröffentlicht Nachtrag zum Kotierungsprospekt, einschliesslich Finanzabschluss von Sandoz für das 1. Halbjahr 2023
-
Media ReleaseSandoz publie un supplément au prospectus de cotation comprenant les états financiers de Sandoz au premier semestre 2023
-
Media ReleaseSandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statements
-
Media ReleaseNovartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scission
-
Media ReleaseNovartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 16
- › Next page